administered BPC 157 (10mcg/kg or 10 ng/kg) orally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery to test its effects on short bowel syndrome in rats, observing the effectiveness of both forms of administration [24]
Treatment with heparinase III and hyaluronidase, enzymes degrading glycocalyx components, enhanced neutrophil adhesion
My view has not changed: BPC-157 lacks adequate human evidence for ulcerative colitis, Crohn's disease or "gut healing", and it should not replace established IBD treatment
| 2024 Edition Qualified researchers and laboratory professionals may purchase GHK-Cu online in either injectable or topical cream format for experimentation
The breadth of proposed effects in the animal literature is unusual for a compound with such a clean mechanistic profile
Potential mechanisms include promoting access of soluble lipases to hydrophobic substrates, facilitating the formation of complexes between lipases and lipolysis-associated proteins, and stabilizing lipases at the surface of the lipid droplet
